PREDICTIVE FACTORS OF LONGITUDINAL BONE LOSS IN PATIENTS TREATED WITH AROMATASE INHIBITORS FOR BREAST CANCER

被引：0
|
作者：
Fowler, J. [1 ,2 ]
Mitchell, K. [1 ,2 ]
Bukhari, M. [1 ,3 ]
机构：
[1] Univ Lancaster, Fac Hlth & Med, Lancaster, England
[2] Univ Hosp Morecambe Bay, Lancaster, England
[3] Univ Hosp Morecambe Bay, Rheumatol Dept, Lancaster, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.2415
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0473
引用
收藏
页码：764 / 765
页数：2
相关论文
共 50 条
  • [1] Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors
    Cepa, M.
    Vaz, C.
    [J]. ACTA REUMATOLOGICA PORTUGUESA, 2015, 40 (04): : 323 - 330
  • [2] BONE LOSS IN WOMEN WITH BREAST CANCER TREATED WITH AROMATASE INHIBITORS
    Zodelava, M.
    Tsikhiseli, G.
    Nijaradze, S.
    Tskhovrebashvili, N.
    Tatishvili, N.
    Tskhovrebashvili, M.
    Mamaladze, T.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S465 - S465
  • [3] Prevalence of bone loss among nonmetastatic breast cancer patients treated with aromatase inhibitors in the United States
    Pirolli, M.
    Hernandez, R. K.
    Reich, A.
    Liede, A.
    [J]. CANCER RESEARCH, 2016, 76
  • [4] FACTORS ASOCIATED WITH OSTEOPOROSIS AND BMD LOSS IN A COHORT OF WOMEN WITH BREAST CANCER TREATED WITH AROMATASE INHIBITORS
    Loarce-Martos, J.
    Sifuentes-Giraldo, W. A.
    Maldonado-Romero, L. V.
    Ahijon-Lana, M.
    Velazquez-Arce, C.
    Martinez-Janez, N.
    Vazquez-Diaz, M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S445 - S445
  • [5] Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors
    Gunmalm, V.
    Jorgensen, N. R.
    Abrahamsen, B.
    Schwarz, P.
    [J]. EUROPEAN GERIATRIC MEDICINE, 2017, 8 (5-6) : 408 - 412
  • [6] Bone mineral density screening and monitoring in early breast cancer patients treated with aromatase inhibitors
    Gilani, S.
    Ikram, N.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S227 - S227
  • [7] Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
    Kwan, Marilyn L.
    Lo, Joan C.
    Tang, Li
    Laurent, Cecile A.
    Roh, Janise M.
    Chandra, Malini
    Hahn, Theresa E.
    Hong, Chi-Chen
    Sucheston-Campbell, Lara
    Hershman, Dawn L.
    Quesenberry, Charles P., Jr.
    Ambrosone, Christine B.
    Kushi, Lawrence H.
    Yao, Song
    [J]. PLOS ONE, 2014, 9 (10):
  • [8] Impact of aromatase inhibitors on bone health in breast cancer patients
    Geisler, Jurgen
    Lonning, Per E.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 118 (4-5): : 294 - 299
  • [9] Prevalence and risk factors of dry eye disease in patients treated with aromatase inhibitors for breast cancer
    Machairoudia, Genovefa
    Kazantzis, Dimitrios
    Chatziralli, Irini
    Kampoli, Katerina
    Ntavatzikos, Anastasios
    Theodossiadis, Panagiotis
    Koumarianou, Anna
    [J]. CLINICAL AND EXPERIMENTAL OPTOMETRY, 2024, 107 (04) : 415 - 419
  • [10] Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women
    不详
    [J]. Drugs & Therapy Perspectives, 2009, 25 (10) : 23 - 26
12345